WS #16508
Eli Lilly reported a massive Q3 beat with EPS of $7.48 vs $6.61 estimates and revenue of $24.4B, driven by surging demand for Zepbound and Mounjaro. This performance cements the GLP-1 narrative as the primary growth engine in healthcare, outpacing peers like Novo Nordisk. The strong results validate the sector's pricing power and demand visibility, making it a key defensive growth play amidst broader tech volatility.
GLP-1 Dominance & Pharma Strength
Eli Lilly reported a massive Q3 beat with EPS of $7.48 vs $6.61 estimates and revenue of $24.4B, driven by surging demand for Zepbound and Mounjaro. This performance cements the GLP-1 narrative as the primary growth engine in healthcare, outpacing peers like Novo Nordisk. The strong results validate the sector's pricing power and demand visibility, making it a key defensive growth play amidst broader tech volatility.